Revolution Medicines Inc. (RVMD)
| Bid | 46.65 |
| Market Cap | 8.73B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -812.06M |
| EPS (ttm) | -4.72 |
| PE Ratio (ttm) | -9.9 |
| Forward PE | -7.71 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 48 |
| Volume | 1,756,702 |
| Avg. Volume (20D) | 2,184,753.4 |
| Open | 45.98 |
| Previous Close | 45.70 |
| Day's Range | 45.72 - 47.59 |
| 52-Week Range | 29.17 - 62.40 |
| Beta | 1.26 |
| Ex-Dividend Date | n/a |
About RVMD
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for RVMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAnalysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm SoldRevolution Medicines, Inc. shares surged on strong Phase 1 data for daraxonrasib in metastatic pancreatic cancer, showing high response and disease control rates. Daraxonrasib demonstrated superior ef...
1 month ago · https://thefly.com
Piper starts Revolution Medicines at Overweight on daraxonrasib potentialPiper Sandler analyst Kelsey Goodwin last night initiated coverage of Revolution Medicines with an Overweight rating and $75 price target. The firm believes the stock's value will be driven by confide...
1 month ago · seekingalpha.com
Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call TranscriptRevolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Anthony Mancini - Chief Global Commercialization Officer Jack Anders - Chief F...
